- Home
- LCNB vs DRUG Comparison
LCNB vs DRUG Comparison
Compare LCNB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCNB
- DRUG
- Stock Information
- Founded
- LCNB 1877
- DRUG 2019
- Country
- LCNB United States
- DRUG United States
- Employees
- LCNB N/A
- DRUG N/A
- Industry
- LCNB Major Banks
- DRUG Pharmaceuticals and Biotechnology
- Sector
- LCNB Finance
- DRUG Health Care
- Exchange
- LCNB Nasdaq
- DRUG Nasdaq
- Market Cap
- LCNB 205.5M
- DRUG 199.7M
- IPO Year
- LCNB N/A
- DRUG N/A
- Fundamental
- Price
- LCNB $15.35
- DRUG $43.48
- Analyst Decision
- LCNB
- DRUG Strong Buy
- Analyst Count
- LCNB 0
- DRUG 7
- Target Price
- LCNB N/A
- DRUG $83.25
- AVG Volume (30 Days)
- LCNB 20.6K
- DRUG 54.0K
- Earning Date
- LCNB 07-22-2025
- DRUG 08-26-2025
- Dividend Yield
- LCNB 5.79%
- DRUG N/A
- EPS Growth
- LCNB 186.06
- DRUG N/A
- EPS
- LCNB 1.49
- DRUG N/A
- Revenue
- LCNB $86,864,000.00
- DRUG N/A
- Revenue This Year
- LCNB N/A
- DRUG N/A
- Revenue Next Year
- LCNB $6.72
- DRUG N/A
- P/E Ratio
- LCNB $10.20
- DRUG N/A
- Revenue Growth
- LCNB 22.73
- DRUG N/A
- 52 Week Low
- LCNB $13.34
- DRUG $0.94
- 52 Week High
- LCNB $17.92
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- LCNB 54.46
- DRUG 77.56
- Support Level
- LCNB $14.33
- DRUG $34.19
- Resistance Level
- LCNB $15.69
- DRUG $43.00
- Average True Range (ATR)
- LCNB 0.43
- DRUG 3.10
- MACD
- LCNB 0.05
- DRUG 0.66
- Stochastic Oscillator
- LCNB 68.79
- DRUG 85.96
About LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.